Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose-escalation Study of Topotecan in Moderate-severe COVID-19 Patients

NCT05083000 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT05083000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05083000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose-escalation Study of Topotecan in Moderate-severe COVID-19 Patients
Lead sponsor
National University Hospital, Singapore
Phase
Phase 1
Overall status
Unknown status
Start date
August 16, 2021
Completion date
March 31, 2022
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 respiratory infection